54 results about "Neurologic Dysfunctions" patented technology

Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

An automated intelligent computer system for analyzing motor or locomotor behavior and method of use is provided. The system comprises an automatic, objective, fast and consistent assessment of the level of injury and course of recovery in animal models of spinal cord injury and other gait and motor coordination disorders. The system also is useful for analyzing other types of motor or neurologic dysfunction.

The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.

It is intended to provide a method of efficiently inducing the growth of nerve stem cells, which are most important in transplantation therapy for nerve damage and neurological dysfunction, either in vitro or in vivo, a method of using the nerve stem cells obtained by the above growth induction method, etc. A mammalian nerve tissue containing nerve stem cells is separated and the nerve stem cells are selectively cultured in a medium containing growth factors such as EGF and FGF. Next, the nerve stem cells are co-cultured with dendritic cell such as an immature dendritic cell subset having a CD11c surface marker on the cell surface, spleen cells or blood cell-type cells such as CD8-positive T cells. Alternatively, the nerve stem cells after the culture are further cultured in the presence of GM-CSF or the nerve stem cells after the culture are further cultured in a culture supernatant of dendritic cells or a culture supernatant of blood cell-type cells.

It is intended to provide a drug which is efficacious in treating a prion disease and has a high safety. A remedy for a prion disease which contains a mesenchymal stem cell as the active ingredient and a method of producing the same. A remedy for a prion disease which contains a mesenchymal stem cell, in particular, a mesenchymal stem cell having an anti-prion antibody gene transferred thereinto as the active ingredient and a method of producing the same. These remedies can not only prevent the progress of a prion disease but also contribute to the recovery of nerve dysfunction caused by the disease.

The invention relates to the use of human lysozyme in pharmaceutical industry, in particular the use in preparing medicines for treating dermatosis, infection and ulceration caused by bacteria, fungus, viruses, allergic reaction, and occupational diseases, physical diseases, nerve dysfunctional diseases, and immunity diseases. The invention exploits the novel use of human lysozyme in medical treatment, the gene recombination lysozyme has rich source, the invention also features simple process for manufacturing, and ease in use.

A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A.

The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered topically or transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day. In homeopathic use, the reserpine may be administered in the form of a homeopathic dilution, preferably as a 12 C homeopathic dilution of reserpine.

A method of diagnosing and monitoring biologic dysfunction may include performing measurements utilizing sensors of wireless earpieces, analyzing the measurements, comparing the measurements to established norms, determining whether the measurements indicate biologic dysfunction. The measurements may include biologic data of a user or environmental data. The sensors may include inertial sensors or optical sensors. The biologic dysfunction may include neurologic dysfunction and the neurologic dysfunction may include intention tremor. The method may include reporting the biologic dysfunction to a user.

A non-invasive quantitative somatosensory apparatus is provided for evaluating erectile dysfunctions and involves the applications to the glans penis of two different temperatures. If the patient is unable to differentiate the difference in temperature, a diagnosis of neurologic dysfunction can be made with greater than 90% reliability. The apparatus of this invention provides a relatively simple device to assess a patient's neurological response to therapies.

A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered topically or transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day.

A system for evaluating neurologic dysfunction of a subject includes an odorant generator configured to deliver an odorant stimulation to the subject, an auditory generator configured to deliver an audible stimulation to the subject, a vibrotactile stimulator configured to generate a somatosensory stimulation to the subject, a plurality of electrodes configured to be attached to the subject at respective different locations, and at least one processor. The plurality of electrodes are configured to collect neural signals from the subject as a result of the odorant stimulation, the audible stimulation, and the somatosensory stimulation. The at least one processor is configured to process the neural signals from the plurality of electrodes and generate an assessment of neurologic dysfunction of the subject.

The invention provides neuron-derived cells obtained by transfecting a receptor-expressing nucleic acid having an aryl hydrocarbon receptor gene, wherein outgrowth of neurites is not observed without adding a substance for the aryl hydrocarbon receptor, and outgrowth of neurites is observed by adding the substance for the aryl hydrocarbon receptor. The invention also provides a method for determining the presence of neurotoxicity of a test substance, a method for acquiring a marker for determining the presence of neurotoxicity of the test substance, a method for acquiring a marker for neurological dysfunction, and a method for determining the effect of the test substance on neurological dysfunction using such cells.

Provided are a use of 5α-androstane-3β,5,6β-triol and analogues thereof in the preparation of a drug for treating or preventing altitude sickness induced by hypobaric hypoxia.

The invention relates to application of an anti-CAMK2A autoantibody reagent in preparation of a kit for diagnosing nervous system symptom related diseases, and belongs to the technical field of disease diagnosis kits. The invention provides an application of an anti-CAMK2A autoantibody reagent in preparation of a kit for diagnosing diseases related to nervous system symptoms. The kit prepared by the application can realize the detection of the CAMK2A autoantibody, and can be used for diagnosing nervous system diseases, especially nervous system diseases related to one or more symptoms; wherein the symptoms comprise sleep disorder, sleepiness, depression, cognitive and mental disorder, autonomic nerve dysfunction, epileptic seizure, consciousness level decline and consciousness blurring. The kit can also be used for distinguishing autoimmune diseases, especially autoimmune diseases and non-autoimmune diseases of a nervous system.

The invention relates to a novel pharmacological action of a traditional Chinese medicine monomer salvianolic acid A, and applications of the salvianolic acid A in preparing products for preventing, relieving and/or treating including muscular atrophy, myopathy, musculoskeletal complications and complications thereof caused by various reasons including diabetes, heredity, muscular dystrophy and neurological dysfunction. The salvianolic acid A has the advantages that: the salvianolic acid A has the effects of delaying and treating muscular atrophy caused by various reasons and diabetes, increasing skeletal muscle strength, improving skeletal muscle tissue microcirculation, increasing skeletal muscle weight, and improving pathological injury of skeletal muscle tissues. The salvianolic acid Ais a monomer compound extracted from danshen roots, has low toxicity and wide raw material resources, has good application and development prospects, and can be used for preventing, relieving and treating muscular atrophy, diabetic myopathy, diabetic muscular atrophy, diabetic musculoskeletal complications and complications thereof caused by various reasons.

Disclosed herein are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal mal is suffering from or is at risk of developing Alzheimer's Disease. The claimed compounds have the structure of formula (I) wherein: L is N or CR5, M is N or CR6; P is N or CR7; and Q is N or CR8; X is a bond or is Cl-14alkyl, wherein at least one carbon is optionally replaced by C(O), 0, S, S02, or NH, NH-Cl-8alkyl, and wherein at least one H of Cl-8alkyl is optionally replaced by halo, OH, Cl-6alkyl; wherein at least one halo is optionally replaced with a radionuclide or a fluorescent tag. The other variables are as defined in the claims.

The invention discloses a system and a method for formulating an acoustic stimulation nerve regulation treatment scheme. The system comprises a signal input and analysis unit for auditory and/or non-auditory detection, an acoustic stimulation scheme formulating and storing unit and an acoustic stimulation scheme implementing unit. Through the mode, the system and the method for formulating the acoustic stimulation nerve regulation treatment scheme can accurately formulate and implement a multi-course nerve regulation and control treatment and rehabilitation scheme combining a physiological part and a psychological part of a large class of chronic diseases such as refractory neurological dysfunction according to a personalized detection result, tracking, objective evaluation and development prediction of multiple treatment effects are regularly performed, the treatment effect of a subsequent treatment scheme is qualitatively and quantitatively regulated and optimized, the change of a neural function state is predicted, and a complete-cycle management scheme for various neurological dysfunction chronic diseases is formulated and implemented.

The invention discloses a preparation method of a traditional Chinese medicine preparation and application of the preparation in treatment of vertigo. The traditional Chinese medicine preparation is prepared from, by weight, 25-35 parts of radix aconiti lateralis preparata, 10-20 parts of rhizoma zingiberis, 10-20 parts of morinda officinalis, 10-20 parts of cassia twig, 10-20 parts of rhizoma pinellinae praeparata, 10-20 parts of rhizoma acori tatarinowii, 10-20 parts of radix notoginseng, 10-20 parts of epimedium herbs, 10-20 parts of radix ginseng cruda and 3-9 parts of radix et rhizoma rhei. According to the traditional Chinese medicine preparation, vertigo caused by various diseases can be effectively treated, the treatment method mainly takes internal adjustment as a principal step,the neurologic dysfunction of patients can be fundamentally relieved, the preparation can also assist in prevention of the cardiovascular diseases, cranial vascular diseases, stroke and other important diseases, and the preparation has the functions of tonifying kidney-yang, clearing heat and eliminating phlegm, tonifying the liver and kidney, dissipating dampness and promoting appetite, clearingthe heart and restoring consciousness, adjusting the immune function and the like.

Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present, for use in the prevention or treatment of frailty in a mammal, wherein frailty is determined by compliance with at least 2 criterions, preferably 3 criterions, selected from the group of muscle weakness, excessive feelings of exhaustion or fatigue, abnormally low physical activity, slow or unsteady gait, weight loss, and neurological dysfunction.

We recently found that Satb1 is expressed highly by mature neurons in specific regions of the postnatal brain. Satb2, a homolog of Satb1, is expressed at low levels in the postnatal brain. Neurons respond to external stimuli and rapidly and dynamically change their expression. Satb1 has been found to directly regulate a set of genes in the postnatal brain, presumably playing a crucial role as a ‘genome organizer’ for brain function and behaviors. Satb2 may also have a similar function, even though it is expressed at low levels in the postnatal brain. The present invention describes compositions, reagents and tools using wild type and variant SATB1 and SATB2 genes and proteins for use in diagnosis, prognosis and therapeutics in neurological dysfunction and psychiatric disorders.